The estimated Net Worth of Alexander Cumbo is at least $14.5 Million dollars as of 2 December 2023. Mr. Cumbo owns over 28,612 units of Sarepta Therapeutics Inc stock worth over $3,748,474 and over the last 8 years he sold SRPT stock worth over $7,613,638. In addition, he makes $3,115,160 as Executive Vice President and Chief Commercial Officer at Sarepta Therapeutics Inc.
Sign up
Mr. Cumbo SRPT stock SEC Form 4 insiders trading
Alexander has made over 6 trades of the Sarepta Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 28,612 units of SRPT stock worth $3,673,495 on 2 December 2023.
The largest trade he's ever made was selling 42,000 units of Sarepta Therapeutics Inc stock on 13 December 2019 worth over $5,271,000. On average, Alexander trades about 6,391 units every 116 days since 2017. As of 2 December 2023 he still owns at least 29,196 units of Sarepta Therapeutics Inc stock.
You can see the complete history of Mr. Cumbo stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Alexander Cumbo biography
Alexander Cumbo is Executive Vice President and Chief Commercial Officer of the Company. Prior to this appointment, he served as our Senior Vice President, Chief Commercial Officer from May 2017 to February 2019, Senior Vice President of Global Commercial Organization from October 2016 to May 2017, Vice President, Global Commercial Development from September 2015 to September 2016 and Vice President, Global Business and Commercial Development from January 2013 to August 2015. From June 2010 to January 2013, Mr. Cumbo worked at Vertex Pharmaceuticals Inc., a biopharmaceutical company, where he served as Vice President of Sales and Treatment Education for the launch of Incivek. Prior to working at Vertex, Mr. Cumbo worked for Gilead Sciences, a biopharmaceutical company, for nine years in multiple commercial roles supporting the HIV, HBV and Cardiovascular franchises. Mr. Cumbo started his career at GlaxoSmithKline plc and has over twenty years of pharmaceutical and biotechnology experience. Mr. Cumbo has served as a member of the Board of Directors of Ra Pharmaceuticals, Inc., a publicly-traded clinical-stage biopharmaceutical company, since November 2018. Mr. Cumbo holds a Bachelor of Science (B.S.) in Medical Technology from Auburn University.
What is the salary of Alexander Cumbo?
As the Executive Vice President and Chief Commercial Officer of Sarepta Therapeutics Inc, the total compensation of Alexander Cumbo at Sarepta Therapeutics Inc is $3,115,160. There are 3 executives at Sarepta Therapeutics Inc getting paid more, with Gilmore O'Neill having the highest compensation of $5,168,110.
How old is Alexander Cumbo?
Alexander Cumbo is 49, he's been the Executive Vice President and Chief Commercial Officer of Sarepta Therapeutics Inc since 2019. There are 13 older and 4 younger executives at Sarepta Therapeutics Inc. The oldest executive at Sarepta Therapeutics Inc is Hans Wigzell, 82, who is the Independent Director.
What's Alexander Cumbo's mailing address?
Alexander's mailing address filed with the SEC is C/O SOLID BIOSCIENCES INC., 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN, MA, 02129.
Insiders trading at Sarepta Therapeutics Inc
Over the last 12 years, insiders at Sarepta Therapeutics Inc have traded over $58,674,663 worth of Sarepta Therapeutics Inc stock and bought 827,614 units worth $49,516,406 . The most active insiders traders include John C Martin, Richard Barry, and M Kathleen Behrens. On average, Sarepta Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $2,737,275. The most recent stock trade was executed by Ian Michael Estepan on 30 August 2024, trading 5,985 units of SRPT stock currently worth $822,100.
What does Sarepta Therapeutics Inc do?
sarepta therapeutics is a biopharmaceutical company focused on the discovery and development of unique rna-targeted therapeutics for the treatment of rare, infectious and other diseases. the company is primarily focused on rapidly advancing the development of its potentially disease-modifying dmd drug candidates, including its lead dmd product candidate, eteplirsen, designed to skip exon 51. sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases. for more information, please visit us at www.sarepta.com.
What does Sarepta Therapeutics Inc's logo look like?
Complete history of Mr. Cumbo stock trades at Sarepta Therapeutics Inc and Solid Biosciences Inc
Sarepta Therapeutics Inc executives and stock owners
Sarepta Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Gilmore O'Neill,
Executive Vice President, R&D and Chief Medical Officer -
William Ciambrone,
Executive Vice President - Technical Operations -
David Howton,
Executive Vice President, General Counsel, Secretary -
Alexander Cumbo,
Executive Vice President and Chief Commercial Officer -
Douglas Ingram,
President, Chief Executive Officer, Director -
Douglas S. Ingram,
Pres, CEO & Director -
Dr. Gilmore O'Neill M.D.,
Exec. Officer -
Dr. Louise Rodino-Klapac Ph.D.,
Chief Scientific Officer and Head of R&D -
Ian Michael Estepan,
Exec. VP & CFO -
William F. Ciambrone,
Exec. VP of Technical Operations -
M. Kathleen Behrens,
Independent Chairwoman of the Board -
Richard Barry,
Independent Director -
Hans Wigzell,
Independent Director -
Claude Nicaise,
Independent Director -
Mary Gray,
Independent Director -
John Martin,
Independent Director -
Joseph Bratica,
Interim Principal Financial and Accounting Officer -
Dr. Diane L. Berry,
Sr. VP of Global Health Policy and Gov. & Patient Affairs -
Alison Nasisi,
Chief People Officer & VP -
Ryan E. Brown,
Sr. VP, Gen. Counsel & Corp. Sec. -
Mary Jenkins,
Sr. Mang. of Investor Relations -
Michael W Bonney,
Director -
Ben Gil Price,
Director -
Catherine Stehman Breen,
SVP, Chief Medical Officer -
Jayant Aphale,
SVP Technical Operations -
Jean Paul Kress,
Director -
William Alden Goolsbee,
Director -
Shamim Ruff,
SVP, Chief Regulatory Affairs -
Sandesh Mahatme,
EVP, CFO & CBO -
Guriqbal S. Basi,
SVP, Chief Scientific Officer -
Michael A Jacobsen,
VP of Finance and PAO -
Anthony Martignetti,
-
Nishan Garabedian Christopher,
President and CEO -
Anthony R Chase,
Director -
John Hodgman,
Director -
Arthur M Krieg,
SVP, Chief Scientific Officer -
Edward M. Md Kaye,
SVP & Chief Medical Officer -
Ian Michael Estepan,
Chief Financial Officer -
Ryan Edward Brown,
EVP, General Counsel -
Louise Rodino Klapac,
Head of R&D, CSO -
Bilal Arif,
Chief Tech Ops Officer -
Stephen Mayo,
-
Kathryn Jean Boor,
-
Dallan Murray,
Chief Customer Officer